An Open-Source Monte Carlo Ray-Tracing Simulation Tool for Luminescent Solar Concentrators with Validation Studies Employing Scattering Phosphor Films Dahkki Duncan E. Smith, Michael D. Hughes, Bhakti Patel, Diana-Andra Borca-Tasciuc

Viečča ollesdeavstta

Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials Dahkki McNeil Ngongondo, Justin Ritz, Michael D. Hughes, Mitch Matoga, Mina C. Hosseinipour

Viečča ollesdeavstta

Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infecte... Dahkki Amita Gupta, Michael D Hughes, Anthony J Garcia-Prats, Katherine McIntire, Anneke C Hesseling

Viečča ollesdeavstta

Statistical methodologies for evaluation of the rate of persistence of Ebola virus in semen of male survivors in Sierra Leone Dahkki Ndema Habib, Michael D. Hughes, Nathalie Broutet, Anna Thorson, Philippe Gaillard, Sihem Landoulsi, Suzanne L. R. McDonald, Pierre Formenty

Viečča ollesdeavstta

Qualitative interviews to evaluate content validity of the ACTIV-2 COVID-19 Symptom Diary (ACSD) Dahkki Louis S. Matza, Katie D. Stewart, April N. Naegeli, Kayla M. Mills, Karin S. Coyne, Kara W. Chew, Michael D. Hughes, Davey M. Smith

Viečča ollesdeavstta

Decreased diarrheal and respiratory disease in HIV exposed uninfected children following vaccination with rotavirus and pneumococcal conjugate vaccines. Dahkki Gbolahan Ajibola, Kara Bennett, Kathleen M Powis, Michael D Hughes, Jean Leidner, Samuel Kgole, Oganne Batlang, Mompati Mmalane, Joseph Makhema, Shahin Lockman, Roger Shapiro

Viečča ollesdeavstta

Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults. Dahkki Mary F Kearney, Jonathan Spindler, Ann Wiegand, Wei Shao, Richard Haubrich, Sharon Riddler, Christina M Lalama, Michael D Hughes, John M Coffin, John W Mellors

Viečča ollesdeavstta

Pathological and clinical outcomes following neoadjuvant dual HER2 therapy for early‐stage breast cancer: An Australian institutional real‐world experience Dahkki Sathya Narayanan, Nicholas K. Ngui, Ben Kinchington, Joseph Do Woong Choi, Thomas Michael D. Hughes, Josie Rutovitz, Csilla Hasovits, Kazi J. Nahar, Senarath Edirimanne, Gavin Marx

Viečča ollesdeavstta

Statistical methodologies for evaluation of the rate of persistence of Ebola virus in semen of male survivors in Sierra Leone. Dahkki Ndema Habib, Michael D Hughes, Nathalie Broutet, Anna Thorson, Philippe Gaillard, Sihem Landoulsi, Suzanne L R McDonald, Pierre Formenty, Sierra Leone Ebola Virus Persistence Study Group

Viečča ollesdeavstta

Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials. Dahkki McNeil Ngongondo, Justin Ritz, Michael D Hughes, Mitch Matoga, Mina C Hosseinipour, AIDS Clinical Trials Group A5208, A5221, A5175 and A5274 Study Teams

Viečča ollesdeavstta

Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants. Dahkki Scott Dryden-Peterson, Oluwemimo Jayeoba, Michael D Hughes, Haruna Jibril, Kenneth McIntosh, Taolo A Modise, Aida Asmelash, Kathleen M Powis, Max Essex, Roger L Shapiro, Shahin Lockman

Viečča ollesdeavstta

Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistanc... Dahkki Robert A. Salata, Beatriz Grinsztejn, Justin Ritz, Ann C. Collier, Evelyn Hogg, Robert Gross, Catherine Godfrey, Nagalingeswaran Kumarasamy, Cecilia Kanyama, John W. Mellors, Carole L. Wallis, Michael D. Hughes, the ACTG A5288 Study Team

Viečča ollesdeavstta

Similar HIV protection from four weeks of zidovudine versus nevirapine prophylaxis among formula-fed infants in Botswana Dahkki Kathleen M. Powis, Shahin Lockman, Gbolahan Ajibola, Michael D. Hughes, Kara Bennett, Jean Leidner, Oganne Batlang, Kerapetse Botebele, Sikhulile Moyo, Erik van Widenfelt, Joseph Makhema, Chipo Petlo, Haruna B. Jibril, Kenneth McIntosh, Max Essex, Roger L. Shapiro

Viečča ollesdeavstta

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. Dahkki Athe M N Tsibris, Bette Korber, Ramy Arnaout, Carsten Russ, Chien-Chi Lo, Thomas Leitner, Brian Gaschen, James Theiler, Roger Paredes, Zhaohui Su, Michael D Hughes, Roy M Gulick, Wayne Greaves, Eoin Coakley, Charles Flexner, Chad Nusbaum, Daniel R Kuritzkes

Viečča ollesdeavstta

An augmented SMS intervention to improve access to antenatal CD4 testing and ART initiation in HIV-infected pregnant women: a cluster randomized trial. Dahkki Scott Dryden-Peterson, Kara Bennett, Michael D Hughes, Adrian Veres, Oaitse John, Rosina Pradhananga, Matthew Boyer, Carolyn Brown, Bright Sakyi, Erik van Widenfelt, Koona Keapoletswe, Madisa Mine, Sikhulile Moyo, Aida Asmelash, Mark Siedner, Mompati Mmalane, Roger L Shapiro, Shahin Lockman

Viečča ollesdeavstta

The statistical design and analysis of pandemic platform trials: Implications for the future – CORRIGENDUM Dahkki Christopher J. Lindsell, Matthew Shotwell, Kevin J. Anstrom, Scott Berry, Erica Brittain, Frank E. Harrell, Nancy Geller, Birgit Grund, Michael D. Hughes, Prasanna Jagannathan, Eric Leifer, Carlee B. Moser, Karen L. Price, Michael Proschan, Thomas Stewart, Sonia Thomas, Giota Touloumi, Lisa LaVange

Viečča ollesdeavstta

The statistical design and analysis of pandemic platform trials: Implications for the future Dahkki Christopher J. Lindsell, Matthew Shotwell, Kevin J. Anstrom, Scott Berry, Erica Brittain, Frank E. Harrell, Nancy Geller, Birgit Grund, Michael D. Hughes, Prasanna Jagannathan, Eric Leifer, Carlee B. Moser, Karen L. Price, Michael Proschan, Thomas Stewart, Sonia Thomas, Giota Touloumi, Lisa LaVange

Viečča ollesdeavstta

Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody. Dahkki Tin Phan, Carolin Zitzmann, Kara W Chew, Davey M Smith, Eric S Daar, David A Wohl, Joseph J Eron, Judith S Currier, Michael D Hughes, Manish C Choudhary, Rinki Deo, Jonathan Z Li, Ruy M Ribeiro, Ruian Ke, Alan S Perelson, ACTIV-2/A5401 Study Team

Viečča ollesdeavstta

Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies Dahkki Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Mark J. Giganti, Justin Ritz, Michael Gibbs, Hervé Tchouakam Kouekam, Mark T. Esser, Eric S. Daar, Manish Choudhary, Rinki Deo, Courtney V. Fletcher, Jonathan Z. Li, Michael D. Hughes, Davey Smith, David Alain Wohl

Viečča ollesdeavstta

ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic Dahkki Maryam Keshtkar-Jahromi, Kevin J. Anstrom, Christina Barkauskas, Samuel M. Brown, Eric S. Daar, William Fischer, Kevin W. Gibbs, Elizabeth S. Higgs, Michael D. Hughes, Prasanna Jagannathan, Lisa LaVange, Christopher J. Lindsell, Seema U. Nayak, Roger Paredes, Mahesh Parmar, Ithan D. Peltan, Michael Proschan, Matthew S. Shotwell, David M. Vock, Tammy Yokum, Stacey J. Adam

Viečča ollesdeavstta